Biocon: Keeping Pace, Not Changing the Race; YesinteK Autoinjector Approval Improves Convenience, Not Market Share

Research evidence excerpt

STEIN FLASHMAIL

18 August 2026

Nandan Kulkarni

India Healthcare

Biocon Ltd

Shirsh Sawarna

Rating

Underperform

Price Target

BIOS.IN

326.00 INR

Biocon: Keeping Pace, Not Changing the Race; Yesintek

Autoinjector Approval Improves Convenience, Not Market Share

On 18 August, Biocon announced U.S. FDA approval of supplemental presentations for Yesintek (ustekinumab), adding 45 mg/0.5

mL and 90 mg/mL single-dose prefilled autoinjectors. We view the approval as modestly positive, providing a short-term boost

to a franchise that is already plateauing in a market increasingly dominated by PBM-driven private label brands. Given Yesintek's

broad formulary positioning and the fact that >90% of maintenance patients already self-administer at home, we strongly believe

that autoinjectors do not open a meaningful new channel; rather, it should improve convenience, adherence and patient

retention, particularly in IBD indication. We estimate the device could contribute roughly US$10-15Mn of annualized sales,

primarily through incremental share capture and retention rather than market expansion. However, the competitive advantage is

likely to prove short-lived. Wezlana and Pyzchiva already offer autoinjectors presentations, while Celltrion and Alvotech

are expected to narrow the device gap over the next 8-12 months. More importantly, we believe the longer-term outlook for

the ustekinumab class is degrowing faster than street’s estimates due to growing clinical and commercial momentum of

selective IL-23 therapies such as Skyrizi and Tremfya, which continue to gain share across key indications. We therefore view

today's approval as an important competitive catch-up that strengthens Yesintek's positioning within ustekinumab, but one that is

unlikely to materially alter Biocon's medium-term growth trajectory nor the challenges in its execution blueprint. We maintain our

Underperform rating on Biocon.

EXPECTED CHANGE TO CONSENSUS EARNINGS

>-10%

-7%

-5%

-3%

No Change

+3%

+5%

+7%

>+10%

Yesintek® is Biocon's Biosimilar to J&J's Stelara®, and originally approved by the FDA in November 2024 and launched in the U.S. in

…